Callan Family Office LLC Purchases New Shares in Revvity Inc. $RVTY

Callan Family Office LLC purchased a new position in shares of Revvity Inc. (NYSE:RVTY) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,645 shares of the company’s stock, valued at approximately $256,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its stake in shares of Revvity by 138.8% in the 2nd quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after purchasing an additional 236 shares during the last quarter. New Age Alpha Advisors LLC acquired a new position in Revvity in the first quarter valued at approximately $44,000. Caitong International Asset Management Co. Ltd lifted its holdings in Revvity by 25.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 694 shares of the company’s stock valued at $73,000 after buying an additional 140 shares during the period. Cary Street Partners Investment Advisory LLC acquired a new stake in Revvity during the 1st quarter worth $75,000. Finally, Farther Finance Advisors LLC grew its holdings in Revvity by 21.2% during the 1st quarter. Farther Finance Advisors LLC now owns 796 shares of the company’s stock worth $83,000 after acquiring an additional 139 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Analyst Ratings Changes

RVTY has been the topic of several recent research reports. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 3rd. Raymond James Financial reissued an “outperform” rating and issued a $115.00 target price (down previously from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Evercore ISI decreased their target price on Revvity from $108.00 to $106.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Guggenheim assumed coverage on shares of Revvity in a research report on Wednesday. They issued a “neutral” rating on the stock. Finally, Bank of America reduced their price objective on shares of Revvity from $110.00 to $99.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $116.62.

Revvity Price Performance

NYSE RVTY opened at $94.00 on Friday. The firm’s 50 day moving average is $88.46 and its 200-day moving average is $92.53. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $10.91 billion, a PE ratio of 39.83, a price-to-earnings-growth ratio of 3.07 and a beta of 0.98. Revvity Inc. has a 12-month low of $81.36 and a 12-month high of $129.50.

Revvity (NYSE:RVTY) last released its earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.04. The business had revenue of $720.28 million during the quarter, compared to the consensus estimate of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Equities research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity’s dividend payout ratio (DPR) is 11.86%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.